The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Adv Med Sci
; 68(2): 379-385, 2023 Sep.
Article
in En
| MEDLINE
| ID: mdl-37806183
ABSTRACT
PURPOSE:
The primary limiting factor in achieving cures for patients with cancer, particularly ovarian cancer, is drug resistance. The mechanisms of drug resistance of cancer cells during chemotherapy may include compounds of the extracellular matrix, such as the transforming growth factor-beta-induced protein (TGFBI). In this study, we aimed to analyze the TGFBI gene and protein expression in different sensitive and drug-resistant ovarian cancer cell lines, as well as test if TGFBI can be involved in the response to topotecan (TOP) at the very early stages of treatment. MATERIALS ANDMETHODS:
In this study, we conducted a detailed analysis of TGFBI expression in different ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2 and PEO23). The level of TGFBI mRNA (QPCR), intracellular and extracellular protein (Western blot analysis) were assessed in this study.RESULTS:
We observed upregulation of TGFBI mRNA in drug-resistant cell lines and estrogen-receptor positive cell lines, which was supported by overexpression of both intracellular and extracellular TGFBI protein. We also showed the TGFBI expression after a short period of treatment of sensitive ovarian cancer cell lines with TOP.CONCLUSION:
The expression of TGFBI in ovarian cancer cell lines suggests its role in the development of drug resistance.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
Limits:
Female
/
Humans
Language:
En
Journal:
Adv Med Sci
Journal subject:
MEDICINA
Year:
2023
Document type:
Article